Revenue
$6.13B
Fiscal year ended 2026-06-30Operating income
Unavailable
Fiscal year ended 2026-06-30Free cash flow
$567.00M
Fiscal year ended 2026-06-30Organon & Co. (OGN) reported revenue of $6.13B and net income of $209.00M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Organon & Co.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $6.13B |
| Cost of revenue | $2.90B |
| Gross profit | $3.23B |
| Operating income | Unavailable |
| Net income | $209.00M |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $491.00M |
| Income tax expense | $282.00M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $1.71B |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $1.13B |
| Total assets | $13.18B |
| Current assets | $5.11B |
| Total liabilities | $12.17B |
| Current liabilities | $2.62B |
| Total equity incl. NCI | $1.01B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $1.35B |
| Accounts receivable | $1.49B |
| Goodwill | $4.15B |
| Long-term debt | $8.48B |
| Accounts payable | $1.05B |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $737.00M |
| Capital expenditures | $170.00M |
| Investing cash flow | $130.00M |
| Financing cash flow | -$313.00M |
| Net change in cash | $533.00M |
| Stock-based compensation | $75.00M |
| Common dividends paid | $18.00M |
| Common share repurchases | Unavailable |
| Depreciation & amortization | Unavailable |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | $567.00M |
| Gross margin | 52.7% |
| Operating margin | Unavailable |
| FCF margin | 9.3% |
| SBC / revenue | 1.2% |
| Current ratio | 1.95x |
| Revenue YoY growth | -2.5% |
| Net margin | 3.4% |
| R&D / revenue | Unavailable |
| CapEx / revenue | 2.8% |
| Long-term debt / equity | 8.43x |
| Effective tax rate | 57.4% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OGN in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-K/A · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-06View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.